Acute kidney infarction: Not so rare renal disease. A single-center experience with endovascular fibrinolytic therapy

R. Scarpioni, S. De Amicis, Bodini FC Bodini, V. Albertazzi, E. Michieletti
{"title":"Acute kidney infarction: Not so rare renal disease. A single-center experience with endovascular fibrinolytic therapy","authors":"R. Scarpioni, S. De Amicis, Bodini FC Bodini, V. Albertazzi, E. Michieletti","doi":"10.17352/acn.000058","DOIUrl":null,"url":null,"abstract":"Renal Infarction (RI), a rare cause of renal damage characterized by the abrupt interruption of flow in the renal artery, is often recognized late or may even remain undiagnosed since symptoms are non-specific and may be confused with other pathologies, such as pyelonephritis or nephrolithiasis. In situ thrombosis and thromboembolism are the main causes, but often the real cause is, gf unrecognized. The disease is often underdiagnosed and the diagnosis of certainty can be established with ultrasonography Doppler of renal arteries or with second-level diagnostic tools (contrast-enhanced computer tomography, magnetic resonance with gadolinium, and renal scintigraphy) or third level tests (renal arteriography). The therapeutic approach depends on the cause of RI, from the time from onset of ischemia, from the presence of kidney function impairment, and may include systemic anticoagulant therapy, renal angioplasty with or without stenting, loco-regional endovascular fibrinolytic therapy or surgery, as the last chance. In literature, there are neither guidelines nor evidence about any treatment superiority. Here we describe a paradigmatic case in a 51-years-old man hospitalized because of sudden flank pain: the clinical picture, the high serum level. Moreover, we report our 7-years’ experience with 24 cases of RI, mean age 70 /±15 years, 14/24 men, 16/24 presented with hematuria, frequently associated with the history of CKD (16/24). Fifteen of them (62%) were classified as idiopathic and 9 of them were successfully treated with endovascular fibrinolytic treatment. A review of the literature is also provided.","PeriodicalId":127781,"journal":{"name":"Archives of Clinical Nephrology","volume":"7 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Clinical Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17352/acn.000058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Renal Infarction (RI), a rare cause of renal damage characterized by the abrupt interruption of flow in the renal artery, is often recognized late or may even remain undiagnosed since symptoms are non-specific and may be confused with other pathologies, such as pyelonephritis or nephrolithiasis. In situ thrombosis and thromboembolism are the main causes, but often the real cause is, gf unrecognized. The disease is often underdiagnosed and the diagnosis of certainty can be established with ultrasonography Doppler of renal arteries or with second-level diagnostic tools (contrast-enhanced computer tomography, magnetic resonance with gadolinium, and renal scintigraphy) or third level tests (renal arteriography). The therapeutic approach depends on the cause of RI, from the time from onset of ischemia, from the presence of kidney function impairment, and may include systemic anticoagulant therapy, renal angioplasty with or without stenting, loco-regional endovascular fibrinolytic therapy or surgery, as the last chance. In literature, there are neither guidelines nor evidence about any treatment superiority. Here we describe a paradigmatic case in a 51-years-old man hospitalized because of sudden flank pain: the clinical picture, the high serum level. Moreover, we report our 7-years’ experience with 24 cases of RI, mean age 70 /±15 years, 14/24 men, 16/24 presented with hematuria, frequently associated with the history of CKD (16/24). Fifteen of them (62%) were classified as idiopathic and 9 of them were successfully treated with endovascular fibrinolytic treatment. A review of the literature is also provided.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
急性肾梗塞:不是很少见的肾脏疾病。血管内纤溶治疗的单中心经验
肾梗死(RI)是一种罕见的肾损害原因,其特征是肾动脉血流突然中断,由于症状非特异性,可能与肾盂肾炎或肾结石等其他病理相混淆,因此通常发现较晚,甚至可能无法诊断。原位血栓形成和血栓栓塞是主要原因,但真正的原因往往不为人所知。该病常被漏诊,可通过肾动脉超声多普勒检查或二级诊断工具(增强计算机断层扫描、钆磁共振和肾显像)或三级检查(肾动脉造影)确定诊断。治疗方法取决于RI的病因,从缺血开始的时间,从肾功能损害的存在,可能包括全身抗凝治疗,肾血管成形术伴或不伴支架植入,局部区域血管内纤溶治疗或手术,作为最后的机会。在文献中,既没有指南也没有证据表明任何治疗优势。在这里,我们描述一个典型的案例在51岁的男子住院,因为突然的腹部疼痛:临床图片,高血清水平。此外,我们报告了我们7年来24例RI的经验,平均年龄70 /±15岁,14/24男性,16/24表现为血尿,通常与CKD病史相关(16/24)。其中15例(62%)为特发性,9例经血管内溶栓治疗成功。文献综述也提供。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Ochoa syndrome: An overlooked diagnosis – A case report Cystinosis - Pathophysiology Analysis of induction and maintenance immunosuppression choices in the US during the first year post kidney transplant for patients over 70 Studying the efficiency of carbon nano enterosorbents in the model of experimental renal failure The occurrence and influencing factors of fatigue and sleep disturbance in maintenance hemodialysis patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1